Immunotherapy,
Год журнала:
2024,
Номер
16(13), С. 845 - 852
Опубликована: Июль 19, 2024
Dupilumab
has
been
approved
to
treat
a
variety
of
atopic
disorders
and
was
the
first
US
FDA-approved
medication
for
treatment
eosinophilic
esophagitis
(EoE),
initially
in
May
2022,
with
expansion
use
patients
as
young
1
year
age
weighing
at
least
15
kg
January
2024.
It
is
fully
human
monoclonal
antibody
that
inhibits
both
IL-4
IL-13
signaling,
suppressing
TH2-mediated
proinflammatory
cytokines,
chemokines
IgE
implicated
EoE
pathogenesis.
Phase
II
III
trials
have
demonstrated
histologic,
endoscopic
symptomatic
improvement
disease
activity
an
overall
favorable
safety
profile.
This
article
will
review
available
clinical
trial
data
real-world
efficacy
dupilumab
EoE.
Journal of Pediatric Gastroenterology and Nutrition,
Год журнала:
2024,
Номер
79(2), С. 394 - 437
Опубликована: Июнь 24, 2024
Eosinophilic
esophagitis
(EoE)
is
a
chronic
inflammatory
disease
of
the
esophagus
characterized
by
symptoms
esophageal
dysfunction
and
histologically
predominantly
eosinophilic
infiltration
squamous
epithelium.
European
Society
for
Pediatric
Gastroenterology,
Hepatology
Nutrition
(ESPGHAN)
published
guideline
in
2014;
however,
rapid
evolution
knowledge
about
pathophysiology,
diagnostic
criteria,
therapeutic
options
have
made
an
update
necessary.
Therapeutic Advances in Gastroenterology,
Год журнала:
2024,
Номер
17
Опубликована: Янв. 1, 2024
Background:
Eosinophilic
esophagitis
(EoE)
is
recognized
as
a
chronic
type
2
inflammatory
disease
characterized
by
the
eosinophilic
infiltration
of
esophageal
tissue,
posing
significant
burden
and
highlighting
necessity
for
novel
management
strategies
to
address
unmet
clinical
needs.
Objectives:
To
critically
evaluate
existing
literature
on
epidemiology
EoE,
identify
evidence
gaps,
assess
efficacy
current
emerging
treatment
modalities.
Design:
An
extensive
review
was
conducted,
focusing
epidemiological
trends,
diagnostic
challenges,
therapeutic
interventions
EoE.
This
complemented
survey
among
physicians
consultations
with
scientific
expert
panel,
including
patient’s
association
(ESEO
Italia),
enrich
study
findings.
Data
sources
methods:
The
followed
Preferred
Reporting
Items
Systematic
Reviews
Meta-Analyses
(PRISMA)
guidelines,
scrutinizing
studies
research
compile
comprehensive
insights
into
disease’s
landscape.
physician
panel
discussions
aimed
bridge
identified
gaps.
Results:
included
59
51
studies,
uncovering
variable
incidence
prevalence
rates
EoE
globally,
an
estimated
diagnosed
41
per
100,000
in
Italy.
Diagnostic
challenges
were
identified,
nonspecific
symptoms
lack
definitive
biomarkers,
which
complicate
use
endoscopy.
Treatment
options
such
elimination
diets,
proton-pump
inhibitors,
swallowed
corticosteroids
found
have
varying
success
rates,
while
Dupilumab,
therapy
targeting
interleukin
(IL)-4
IL-13,
shows
promise.
Conclusion:
Despite
advancements
understanding
managing
needs
remain,
particularly
biomarker
identification,
personalization,
cost-effectiveness
evaluation.
A
comprehensive,
multidimensional
approach
patient
required,
emphasizing
importance
early
symptom
recognition,
accurate
diagnosis,
tailored
strategies.
Dupilumab
offers
potential
treatment,
underscoring
need
future
explore
economic
social
dimensions
care
pathways.
Expert Review of Gastroenterology & Hepatology,
Год журнала:
2024,
Номер
18(6), С. 271 - 281
Опубликована: Июнь 2, 2024
Eosinophilic
esophagitis
(EoE)
is
a
chronic
inflammatory,
disabling
disorder
characterized
by
prominent
eosinophilic
inflammation
of
the
esophagus,
leading
to
troublesome
symptoms
including
dysphagia
and
food
impaction.
The
natural
history
EoE
poorly
known,
but
it
may
lead
esophageal
strictures.
therapeutic
armamentarium
expected
grow
in
near
future,
especially
due
availability
novel
biological
therapies
targeting
crucial
inflammatory
pathways
EoE.
Педиатрическая фармакология,
Год журнала:
2025,
Номер
21(6), С. 520 - 533
Опубликована: Янв. 9, 2025
Dupilumab
is
a
genetically
engineered
immunobiological
drug
that
has
been
increasingly
used
in
recent
years
to
treat
bronchial
asthma
(BA),
atopic
dermatitis
(AD)
and
eosinophilic
esophagitis
(EE)
children.
The
aim
of
the
study
analyze
current
literature
data
on
use
dupilumab
treatment
BA,
AD
EE
Despite
short
history
pediatric
population,
its
usage
shown
promising
results
many
conditions
whose
pathogenesis
T2
inflammation,
primarily
EE.
It
demonstrated
efficacy
patients
with
various
clinical
manifestations
characterized
by
moderate
severe
course
or
refractory
treatment,
led
an
improvement
quality
life
patients.
With
expansion
dupilumab,
there
more
evidence
usefulness
other
T-cell-mediated
diseases.
